Pfizer Gets PTAB To Wipe Out Rest Of Sanofi's Lantus Patent

Law360 (August 12, 2020, 9:38 PM EDT) -- The Patent Trial and Appeal Board has nixed the two claims left standing in a Sanofi-Aventis patent covering the Lantus SoloStar disposable insulin injection pen after finding back in April in a separate challenge that another claim in the patent was invalid.

Tuesday's decision, which was decided on the briefs, rejected Sanofi's argument that a skilled artisan would not be motivated to combine elements of existing technology because it would increase the injection force, thus requiring a larger pen that would make use by diabetic patients with weakened hands and wrists more difficult.

But the board was not persuaded, saying it...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related Sections

PTAB Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Date Filed

Subscribers Only

Law Firms

Companies

Patents

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!